Seth Harmon
Director of Finance/CFO chez VIRIDIAN THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Seth Harmon is currently the Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. Prior to his current position, he served as the Chief Financial Officer at BioNTech SE from 2020 to 2023.
Before that, he was the Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
Mr. Harmon completed his undergraduate degree at Bowdoin College and holds a graduate degree in MBA from Northeastern University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/11/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Seth Harmon
| Sociétés | Poste | Début |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Director of Finance/CFO | 12/09/2023 |
Anciens postes connus de Seth Harmon
| Sociétés | Poste | Fin |
|---|---|---|
| BIONTECH SE | Director of Finance/CFO | 01/05/2023 |
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2020 |
Formation de Seth Harmon
| Bowdoin College | Undergraduate Degree |
| Northeastern University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIONTECH SE | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
